| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB200-111SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-96140SS | |||
| Azide and BSA Free | NBP2-80599 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-87321-25ul | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB110-40823SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP2-37736-0.025ml | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP3-38286-20ul | |||
![Western Blot: p14ARF/CDKN2A Antibody [NB200-111] - Inhibition of AKT decreases p53mut stability. T24 cells were transfected with non-targeting control, AKT1, or p14ARF siRNA. Cells were treated with NCS348884 (4 i1/4M), Nutlin3A (5 i1/4M) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. Image collected and cropped by Citeab from the following publication (AKT regulates NPM dependent ARF localization and p53mut stability in tumors. Oncotarget (2014)) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Western-Blot-NB200-111-img0012.jpg "<b>Genetic Strategies Validation. </b>Western Blot: p14ARF/CDKN2A Antibody [NB200-111] - Inhibition of AKT decreases p53mut stability. T24 cells were transfected with non-targeting control, AKT1, or p14ARF siRNA. Cells were treated with NCS348884 (4 i1/4M), Nutlin3A (5 i1/4M) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. Image collected and cropped by Citeab from the following publication (AKT regulates NPM dependent ARF localization and p53mut stability in tumors. Oncotarget (2014)) licensed under a CC-BY license.")
![<b>Genetic Strategies Validation. </b>Immunohistochemistry: p14ARF/CDKN2A Antibody [NB200-111] - Inhibition of AKT modulates p53 stability in-vivo and synergizes with ionizing radiation to inhibit tumor growth( Sections of PSN1 xenografts treated with three consecutive doses of MK-2206 (60 mg/kg). Sections of PSN1 xenografts and in-vitro PSN1 cells fixed and stained with anti-NPM (red) and anti-p14ARF (green). Image collected and cropped by Citeab from the following publication (AKT regulates NPM dependent ARF localization and p53mut stability in tumors. Oncotarget (2014)) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Immunocytochemistry-Immunofluorescence-NB200-111-img0011.jpg)
![Immunocytochemistry/Immunofluorescence: p14ARF/CDKN2A Antibody [NB200-111] - p14ARF antibody was tested in HeLa cells with Dylight 488 (green). Nuclei were counterstained with DAPI (blue). Tubulin was stained with alpha tubulin (red).](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Immunocytochemistry-Immunofluorescence-NB200-111-img0006.jpg)
![<b>Biological Strategies Validation. </b>Western Blot: p14ARF/CDKN2A Antibody [NB200-111] - ARF expression levels in OCI/AML3 cells after proteasome treatment. This image was submitted via customer Review.](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Western-Blot-NB200-111-img0009.jpg)
![Flow Cytometry: p14ARF/CDKN2A Antibody [NB200-111] - p14ARF antibody was tested at 1:400 in HeLa cells using an Alexa Fluor 488 secondary (shown in purple). M1 is defined by unstained cells.](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Flow-Cytometry-NB200-111-img0007.jpg)
![Western Blot: p14ARF/CDKN2A Antibody [NB200-111] - Analysis of HeLa Whole Cell Lysate (NB800-PC1) using p14ARF antibody (lot C) employing ECL detection method.](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Western-Blot-NB200-111-img0008.jpg)
![Immunohistochemistry-Frozen: p14ARF/CDKN2A Antibody [NB200-111] - Mouse brain section, hippocampal (10 um thickness). 3% PFA perfused. 1:1000 dilultion. Image from verified customer review. Image using the Biotin form of this antibody.](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Immunohistochemistry-Frozen-NB200-111-img0010.jpg)
![Western Blot: p14ARF/CDKN2A Antibody - BSA Free [NB200-111] - Inhibition of AKT decreases p53mut stability(A) T24 cells & PSN1 cells were treated with MK-2206 (5 μM) or DMSO for 24 hrs. Cells were fixed & stained with DAPI & anti-mutant p53 (OP29 clone). (B) T24 cells were pre-treated with MK-2206 (5 μM) or DMSO for 24 hrs before the addition of fresh media containing cyclohexamide (100 μM) (CHX) in combination with MK-2206 (5 μM) or DMSO for the times indicated. Nuclear extracts were prepared from treated cells & blotted with the indicated antibodies. Quantification is relative to initiation of CHX treatment for both conditions *, MK-2206 is 40% of DMSO control but taken as 1.0 for relative assessment. (C) H1299 cells were transfected with HA-tagged-ubiquitin & mutant p53 (R175H or R248W) as indicated. Transfected cells were treated with DMSO, MK-2206 (5 μM) or Nutlin3A (5 μM) for 16hrs as indicated. p53 immunoprecipitates & whole cell lysates were probed with the indicated antibodies. (D) T24 cells were transfected with non-targeting control or p14ARF siRNA & treated with DMSO, MK-2206 (5 μM) or the NPM oligomerisation inhibitor NCS348884 (4 μM) (Qi et al., 2008) as indicated. (E) T24 cells were transfected with non-targeting control, AKT1, or p14ARF siRNA. Cells were treated with NCS348884 (4 μM), Nutlin3A (5 μM) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. (F) KPC mice derived KRASG12D p53 Floxed (p53Fl), KRASG12D p53R172H ARF+/+ & KRASG12D p53R172H ARF−/− pancreatic tumor cells were treated with MK-2206 (1μM), Nutlin3A (5μM) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25071014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-111_rabbit-polyclonal-p14arf-cdkn2a-antibody-310202416203719.jpg)
![Western Blot: p14ARF/CDKN2A Antibody - BSA Free [NB200-111] - Inhibition of AKT decreases p53mut stability(A) T24 cells & PSN1 cells were treated with MK-2206 (5 μM) or DMSO for 24 hrs. Cells were fixed & stained with DAPI & anti-mutant p53 (OP29 clone). (B) T24 cells were pre-treated with MK-2206 (5 μM) or DMSO for 24 hrs before the addition of fresh media containing cyclohexamide (100 μM) (CHX) in combination with MK-2206 (5 μM) or DMSO for the times indicated. Nuclear extracts were prepared from treated cells & blotted with the indicated antibodies. Quantification is relative to initiation of CHX treatment for both conditions *, MK-2206 is 40% of DMSO control but taken as 1.0 for relative assessment. (C) H1299 cells were transfected with HA-tagged-ubiquitin & mutant p53 (R175H or R248W) as indicated. Transfected cells were treated with DMSO, MK-2206 (5 μM) or Nutlin3A (5 μM) for 16hrs as indicated. p53 immunoprecipitates & whole cell lysates were probed with the indicated antibodies. (D) T24 cells were transfected with non-targeting control or p14ARF siRNA & treated with DMSO, MK-2206 (5 μM) or the NPM oligomerisation inhibitor NCS348884 (4 μM) (Qi et al., 2008) as indicated. (E) T24 cells were transfected with non-targeting control, AKT1, or p14ARF siRNA. Cells were treated with NCS348884 (4 μM), Nutlin3A (5 μM) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. (F) KPC mice derived KRASG12D p53 Floxed (p53Fl), KRASG12D p53R172H ARF+/+ & KRASG12D p53R172H ARF−/− pancreatic tumor cells were treated with MK-2206 (1μM), Nutlin3A (5μM) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25071014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-111_rabbit-polyclonal-p14arf-cdkn2a-antibody-310202416212372.jpg)
![Immunocytochemistry/ Immunofluorescence: p14ARF/CDKN2A Antibody - BSA Free [NB200-111] - Inhibition of AKT modulates p53 stability in-vivo & synergizes with ionizing radiation to inhibit tumor growth(A) PSN1 xenografts (PSN1 cells co-injected with LTC-14 stellate cells) established in the flank of athymic nude mice were treated with MK-2206 (60 mg/kg-320 mg/kg) as indicated or beta -cyclo-dextrin (1.5 mg/ml) carrier. Xenograft tumors were lysed & lysates probed by western blot with the indicated antibodies. (B-D) Sections of PSN1 xenografts treated with three consecutive doses of MK-2206 (60 mg/kg). (B) Sections of PSN1 xenografts & in-vitro PSN1 cells fixed & stained with anti-NPM (red) & anti-p14ARF (green). (C) PSN1 xenografts treated with MK-2206 or carrier were stained with DAPI, anti-p53 (DO1) or p53mut (OP29 clone) (D) PSN1 xenografts treated with MK-2206 (60 mg/kg) or carrier were stained by immunohistochemical methods with anti-pS473-AKT, anti-phospho-S48-NPM (pS48-NPM) or p53. (E) PSN1 xenografts established in the flank of athymic nude mice were injected subcutaneously with two alternate day doses of MK-2206 (60 mg/kg) or carrier. Mice were subsequently treated with a single dose of IR (6 Gy) & tumor volumes measured regularly with callipers. Dash lines indicate tumor growth differential at 250 mm3. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25071014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-111_rabbit-polyclonal-p14arf-cdkn2a-antibody-310202416203724.jpg)
![Western Blot: p14ARF/CDKN2A Antibody - BSA Free [NB200-111] - Inhibition of AKT decreases p53mut stability(A) T24 cells & PSN1 cells were treated with MK-2206 (5 μM) or DMSO for 24 hrs. Cells were fixed & stained with DAPI & anti-mutant p53 (OP29 clone). (B) T24 cells were pre-treated with MK-2206 (5 μM) or DMSO for 24 hrs before the addition of fresh media containing cyclohexamide (100 μM) (CHX) in combination with MK-2206 (5 μM) or DMSO for the times indicated. Nuclear extracts were prepared from treated cells & blotted with the indicated antibodies. Quantification is relative to initiation of CHX treatment for both conditions *, MK-2206 is 40% of DMSO control but taken as 1.0 for relative assessment. (C) H1299 cells were transfected with HA-tagged-ubiquitin & mutant p53 (R175H or R248W) as indicated. Transfected cells were treated with DMSO, MK-2206 (5 μM) or Nutlin3A (5 μM) for 16hrs as indicated. p53 immunoprecipitates & whole cell lysates were probed with the indicated antibodies. (D) T24 cells were transfected with non-targeting control or p14ARF siRNA & treated with DMSO, MK-2206 (5 μM) or the NPM oligomerisation inhibitor NCS348884 (4 μM) (Qi et al., 2008) as indicated. (E) T24 cells were transfected with non-targeting control, AKT1, or p14ARF siRNA. Cells were treated with NCS348884 (4 μM), Nutlin3A (5 μM) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. (F) KPC mice derived KRASG12D p53 Floxed (p53Fl), KRASG12D p53R172H ARF+/+ & KRASG12D p53R172H ARF−/− pancreatic tumor cells were treated with MK-2206 (1μM), Nutlin3A (5μM) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25071014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-111_rabbit-polyclonal-p14arf-cdkn2a-antibody-310202416205197.jpg)
![Western Blot: p14ARF/CDKN2A Antibody - BSA Free [NB200-111] - Inhibition of AKT promotes enhanced MDM2 activity via the increased association between NPM & p14ARF(A) Npm−/−, p53−/−double null MEF were infected with pBABE retrovirus empty vector & pBABE expressing FLAG-tagged-NPM-WT, NPM-S48A or S48E as indicated. Immunopurification of NPM was done by pulling down with the Flag tag (middle panel) followed by elution of complexes by the Flag peptide & subsequent immunopurification of endogenous MDM2 (lower panel). (B) Nuclear immunoprecipitates of MDM2 from T24 cells treated with MK-2206 (5 μM, 24 hrs). Immunoprecipitates & lysates were blotted with the indicated antibodies. (C) T24 cells were treated with MK-2206 (5 μM) as indicated. p14ARF was immunoprecipitated from whole cell lysates & nuclear extracts & the association with NPM & MDM2 determined by western blot. Immunoprecipitates & lysates were blotted with the indicated antibodies. (D) MDM2 & (E) p53 ubiquinitation assay in H1299 cells transfected with wild type p53, HA-tagged ubiquitin & treated for 16 hrs with DMSO, MK-2206 (5 μM) or Nutlin3A (5 μM) as indicated. Immunoprecipitates & whole cell lysates were probed with the indicated antibodies. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25071014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-111_rabbit-polyclonal-p14arf-cdkn2a-antibody-310202416212370.jpg)
![Western Blot: p14ARF/CDKN2A Antibody - BSA Free [NB200-111] - Inhibition of AKT promotes enhanced MDM2 activity via the increased association between NPM & p14ARF(A) Npm−/−, p53−/−double null MEF were infected with pBABE retrovirus empty vector & pBABE expressing FLAG-tagged-NPM-WT, NPM-S48A or S48E as indicated. Immunopurification of NPM was done by pulling down with the Flag tag (middle panel) followed by elution of complexes by the Flag peptide & subsequent immunopurification of endogenous MDM2 (lower panel). (B) Nuclear immunoprecipitates of MDM2 from T24 cells treated with MK-2206 (5 μM, 24 hrs). Immunoprecipitates & lysates were blotted with the indicated antibodies. (C) T24 cells were treated with MK-2206 (5 μM) as indicated. p14ARF was immunoprecipitated from whole cell lysates & nuclear extracts & the association with NPM & MDM2 determined by western blot. Immunoprecipitates & lysates were blotted with the indicated antibodies. (D) MDM2 & (E) p53 ubiquinitation assay in H1299 cells transfected with wild type p53, HA-tagged ubiquitin & treated for 16 hrs with DMSO, MK-2206 (5 μM) or Nutlin3A (5 μM) as indicated. Immunoprecipitates & whole cell lysates were probed with the indicated antibodies. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25071014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-111_rabbit-polyclonal-p14arf-cdkn2a-antibody-310202416205120.jpg)
![Immunocytochemistry/Immunofluorescence: BMI-1 Antibody (LLBmi1-1) [NBP1-96140] - HeLa cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.5% Triton X-100 in PBS for 5 minutes. The cells were incubated with anti- NBP1-96140 at 2 ug/ml overnight at 4C and detected with an anti-mouse Dylight 488 (Green) at a 1:1000 dilution for 60 minutes. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective and digitally deconvolved.](http://images.novusbio.com/fullsize/BMI-1-Antibody-LLBmi1-1-Immunocytochemistry-Immunofluorescence-NBP1-96140-img0008.jpg "Immunocytochemistry/Immunofluorescence: BMI-1 Antibody (LLBmi1-1) [NBP1-96140] - HeLa cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.5% Triton X-100 in PBS for 5 minutes. The cells were incubated with anti- NBP1-96140 at 2 ug/ml overnight at 4C and detected with an anti-mouse Dylight 488 (Green) at a 1:1000 dilution for 60 minutes. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective and digitally deconvolved.")
![Immunocytochemistry/Immunofluorescence: BMI-1 Antibody (LLBmi1-1) [NBP1-96140] - NIH3T3 cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.5% Triton X-100 in PBS for 5 minutes. The cells were incubated with anti- NBP1-96140 at 2 ug/ml overnight at 4C and detected with an anti-mouse Dylight 488 (Green) at a 1:1000 dilution for 60 minutes. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective and digitally deconvolved.](http://images.novusbio.com/fullsize/BMI-1-Antibody-LLBmi1-1-Immunocytochemistry-Immunofluorescence-NBP1-96140-img0009.jpg)
![Western Blot: BMI-1 Antibody (LLBmi1-1) [NBP1-96140] - Western blot analysis of Bmi1 expression in 1) U2OS and 2) K562 whole cell lysates using NBP1-96140.](http://images.novusbio.com/fullsize/BMI-1-Antibody-LLBmi1-1-Western-Blot-NBP1-96140-img0002.jpg)
![Immunocytochemistry/Immunofluorescence: BMI-1 Antibody (LLBmi1-1) [NBP1-96140] - Bmi1 antibody was tested in U2OS cells with FITC (green). Nuclei and alpha-tubulin were counterstained with Dapi (blue) and Dylight 550 (red).](http://images.novusbio.com/fullsize/BMI-1-Antibody-LLBmi1-1-Immunocytochemistry-Immunofluorescence-NBP1-96140-img0003.jpg)
![Flow Cytometry: BMI-1 Antibody (LLBmi1-1) [NBP1-96140] - An intracellular stain was performed on NIH3T3 cells with BMI-1 Antibody (LLBmi1-1) NBP1-96140 (blue) and a matched mouse IgG2b Kappa isotype control (orange) MAB004. Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature, followed by Mouse IgG (H+L) Cross-Adsorbed Secondary Antibody, Dylight 550 (35503, Thermo Fisher).](http://images.novusbio.com/fullsize/BMI-1-Antibody-LLBmi1-1-Flow-Cytometry-NBP1-96140-img0012.jpg)
![Western Blot: BMI-1 Antibody (LLBmi1-1) [NBP1-96140] - BMI-1 expression in human cell lines (MCF-7, K562 and A459). Image from verified customer review.](http://images.novusbio.com/fullsize/BMI-1-Antibody-LLBmi1-1-Western-Blot-NBP1-96140-img0004.jpg)
![Flow Cytometry: BMI-1 Antibody (LLBmi1-1) [NBP1-96140] - An intracellular stain was performed on U2OS cells with BMI-1 Antibody [LLBmi1-1] NBP1-96140AF488 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 488.](http://images.novusbio.com/fullsize/BMI-1-Antibody-LLBmi1-1-Flow-Cytometry-NBP1-96140-img0005.jpg)
![Flow Cytometry: BMI-1 Antibody (LLBmi1-1) [NBP1-96140] - An intracellular stain was performed on U2OS cells with BMI-1 [LLBmi1-1] Antibody NBP1-96140 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 1.0 ug/mL for 30 minutes at room temperature, followed by Mouse IgG (H+L) Cross-Adsorbed Secondary Antibody, Dylight 550 (84540, Thermo Fisher).](http://images.novusbio.com/fullsize/BMI-1-Antibody-LLBmi1-1-Flow-Cytometry-NBP1-96140-img0007.jpg)
![Flow Cytometry: BMI-1 Antibody (LLBmi1-1) [NBP1-96140] - An intracellular stain was performed on U937 cells with BMI-1 Antibody (LLBmi1-1) NBP1-96140 (blue) and a matched mouse IgG2b Kappa isotype control (orange) MAB004. Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature, followed by Mouse IgG (H+L) Cross-Adsorbed Secondary Antibody, Dylight 550 (35503, Thermo Fisher).](http://images.novusbio.com/fullsize/BMI-1-Antibody-LLBmi1-1-Flow-Cytometry-NBP1-96140-img0011.jpg)
![Western Blot: BMI-1 Antibody [NBP1-33748] - Whole cell extract (30 ug) was separated by 10% SDS-PAGE, and the membrane was blotted with BMI-1 antibody diluted at 1:1000. HRP-conjugated anti-rabbit IgG antibody was used to detect the primary antibody.](http://images.novusbio.com/fullsize/BMI-1-Antibody-Western-Blot-NBP1-33748-img0026.jpg "Western Blot: BMI-1 Antibody [NBP1-33748] - Whole cell extract (30 ug) was separated by 10% SDS-PAGE, and the membrane was blotted with BMI-1 antibody diluted at 1:1000. HRP-conjugated anti-rabbit IgG antibody was used to detect the primary antibody.")
![Immunohistochemistry-Paraffin: BMI-1 Antibody [NBP1-33748] - Paraffin-embedded human ovarian carcinoma. Bmi1 antibody dilution: 1:500.](http://images.novusbio.com/fullsize/BMI-1-Antibody-Immunohistochemistry-Paraffin-NBP1-33748-img0023.jpg)
![Western Blot: BMI-1 Antibody [NBP1-33748] - A. 30 ug K562 whole cell lysate/extract B. 30 ug THP-1 whole cell lysate/extract 10% SDS-PAGE Bmi1 antibody dilution: 1:1000 The HRP-conjugated anti-rabbit IgG antibody (NBP2-19301) was used to detect the primary antibody.](http://images.novusbio.com/fullsize/BMI-1-Antibody-Western-Blot-NBP1-33748-img0019.jpg)
![Western Blot: BMI-1 Antibody [NBP1-33748] - A. 30 ug C8D30 whole cell lysate/extract. B. 30 ug BCL-1 whole cell lysate/extract. C. 30 ug Raw264.7 whole cell lysate/extract. 10 % SDS-PAGE. Dilution: 1:1000.](http://images.novusbio.com/fullsize/BMI-1-Antibody-Western-Blot-NBP1-33748-img0020.jpg)
![Western Blot: BMI-1 Antibody [NBP1-33748] - A. 30 ug THP-1 whole cell lysate/extract. B. 30 ug HL-60 whole cell lysate/extract.10 % SDS-PAGE. Dilution: 1:1000](http://images.novusbio.com/fullsize/BMI-1-Antibody-Western-Blot-NBP1-33748-img0021.jpg)
![Immunohistochemistry-Paraffin: BMI-1 Antibody [NBP1-33748] - Paraffin-embedded human breast carcinoma. Bmi1 antibody dilution: 1:500.](http://images.novusbio.com/fullsize/BMI-1-Antibody-Immunohistochemistry-Paraffin-NBP1-33748-img0022.jpg)
![Immunoprecipitation: BMI-1 Antibody [NBP1-33748] - Sample: 293T whole cell lysate/extract A : 30 ug whole cell lysate/extract of BMI-1 protein expressing 293T cells B : Control with 2.5 ug of pre-immune rabbit IgG C : Immunoprecipitation of BMI-1 protein by 2.5 ug of BMI-1antibody 10% SDS-PAGE The immunoprecipitated BMI-1protein was detected by BMI-1 antibody diluted at 1 : 1000. EasyBlot anti-rabbit IgG (HRP) was used as a secondary reagent.](http://images.novusbio.com/fullsize/BMI-1-Antibody-Immunoprecipitation-NBP1-33748-img0018.jpg)
![Western Blot: BMI-1 Antibody [NBP1-33748] - Whole cell extract (30 ug) was separated by 10% SDS-PAGE, and the membrane was blotted with BMI-1 antibody (NBP1-33748) diluted at 1:1000. The HRP-conjugated anti-rabbit IgG antibody was used to detect the primary antibody, and the signal was developed with Trident ECL plus-Enhanced.](http://images.novusbio.com/fullsize/nbp1-33748_rabbit-polyclonal-bmi-1-antibody-9102024209145.jpg)
![Immunohistochemistry-Paraffin: BMI-1 Antibody [NBP1-33748] - BMI-1 antibody detects BMI-1 protein at cytoplasm and nucleus by immunohistochemical analysis.Sample: Paraffin-embedded dog lung.BMI-1 stained by BMI-1 antibody (NBP1-33748) diluted at 1:500.Antigen Retrieval: Citrate buffer, pH 6.0, 15 min](http://images.novusbio.com/fullsize/nbp1-33748_rabbit-polyclonal-bmi-1-antibody-910202420115062.jpg)
![Immunocytochemistry/ Immunofluorescence: BMI-1 Antibody [NBP1-33748] - BMI-1 antibody detects BMI-1 protein at nucleus by immunofluorescent analysis.Sample: MDCK cells were fixed in 4% paraformaldehyde at RT for 15 min.Green: BMI-1 stained by BMI-1 antibody (NBP1-33748) diluted at 1:1000.Red: phalloidin, a cytoskeleton marker, diluted at 1:100.Scale bar= 10 um.](http://images.novusbio.com/fullsize/nbp1-33748_rabbit-polyclonal-bmi-1-antibody-910202419593519.jpg)
![Western Blot: BMI-1 Antibody [NBP1-33748] - Whole cell extract (30 ug) was separated by 10% SDS-PAGE, and the membrane was blotted with BMI-1 antibody (NBP1-33748) diluted at 1:1000. The HRP-conjugated anti-rabbit IgG antibody was used to detect the primary antibody.](http://images.novusbio.com/fullsize/nbp1-33748_rabbit-polyclonal-bmi-1-antibody-910202420131285.jpg)
![Western Blot: BMI-1 Antibody [NBP1-33748] - Whole cell extract (30 ug) was separated by 10% SDS-PAGE, and the membrane was blotted with BMI-1 antibody (NBP1-33748) diluted at 1:1000. The HRP-conjugated anti-rabbit IgG antibody was used to detect the primary antibody.](http://images.novusbio.com/fullsize/nbp1-33748_rabbit-polyclonal-bmi-1-antibody-91020242021927.jpg)
![Immunocytochemistry/ Immunofluorescence: BMI-1 Antibody [NBP1-33748] - BMI-1 antibody detects BMI-1 protein at nucleus by immunofluorescent analysis.Sample: PG-4 cells were fixed in 4% paraformaldehyde at RT for 15 min.Green: BMI-1 stained by BMI-1 antibody (NBP1-33748) diluted at 1:1000.Blue: Hoechst 33342 staining.Scale bar= 10 um.](http://images.novusbio.com/fullsize/nbp1-33748_rabbit-polyclonal-bmi-1-antibody-910202420134048.jpg)
![Western Blot: BMI-1 Antibody [NBP1-33748] - Various whole cell extracts (30 ug) were separated by 10% SDS-PAGE, and the membrane was blotted with BMI-1 antibody (NBP1-33748) diluted at 1:1000. The HRP-conjugated anti-rabbit IgG antibody was used to detect the primary antibody.](http://images.novusbio.com/fullsize/nbp1-33748_rabbit-polyclonal-bmi-1-antibody-91020242063358.jpg)
![<b>Genetic Strategies Validation. </b>Western Blot: BMI-1 Antibody [NBP1-33748] - Non-transfected (–) and transfected (+) HeLa whole cell extracts (30 ug) were separated by 10% SDS-PAGE, and the membrane was blotted with Bmi1 antibody diluted at 1:500. The HRP-conjugated anti-rabbit IgG antibody was used to detect the primary antibody.](http://images.novusbio.com/fullsize/nbp1-33748_rabbit-polyclonal-bmi-1-antibody-1610202419414590.jpg)
![BMI1 antibody [N1C3-2] detects BMI1 protein by immunofluorescent analysis. Sample: HeLa cells were fixed in 4% paraformaldehyde for 15 min. Green: BMI1 protein stained by BMI1 antibody (NBP1-33748) diluted at 1:1000. Blue: Hoechst 33342 staining. Scale bar = 10 um.](http://images.novusbio.com/fullsize/nbp1-33748_rabbit-polyclonal-bmi-1-antibody-immunocytochemistry-immunofluorescence-261120251844101.jpg)
![Western Blot: BMI-1 Antibody (3E3) [NBP2-22204] - Analysis using Bmi1 mAb against human Bmi1 (AA: 1-326) recombinant protein. (Expected MW is 74 kDa)](http://images.novusbio.com/fullsize/BMI-1-Antibody-3E3-Western-Blot-NBP2-22204-img0007.jpg "Western Blot: BMI-1 Antibody (3E3) [NBP2-22204] - Analysis using Bmi1 mAb against human Bmi1 (AA: 1-326) recombinant protein. (Expected MW is 74 kDa)")
![Immunocytochemistry/Immunofluorescence: BMI-1 Antibody (3E3) [NBP2-22204] - Analysis of Hela cells using Bmi1 mouse mAb (green). Blue: DRAQ5 fluorescent DNA dye. Red: Actin filaments have been labeled with Alexa Fluor-555 phalloidin.](http://images.novusbio.com/fullsize/BMI-1-Antibody-3E3-Immunocytochemistry-Immunofluorescence-NBP2-22204-img0002.jpg)
![Immunohistochemistry-Paraffin: BMI-1 Antibody (3E3) [NBP2-22204] - Analysis of paraffin-embedded rectum cancer tissues using Bmi1 mouse mAb with DAB staining.](http://images.novusbio.com/fullsize/BMI-1-Antibody-3E3-Immunohistochemistry-Paraffin-NBP2-22204-img0004.jpg)
![Flow Cytometry: BMI-1 Antibody (3E3) [NBP2-22204] - Analysis of NIH/3T3 cells using Bmi1 mouse mAb (green) and negative control (red).](http://images.novusbio.com/fullsize/BMI-1-Antibody-3E3-Flow-Cytometry-NBP2-22204-img0001.jpg)
![Western Blot: BMI-1 Antibody (3E3) [NBP2-22204] - Analysis using Bmi1 mAb against HEK293 (1) and BMI1-hIgGFc transfected HEK293 (2) cell lysate.](http://images.novusbio.com/fullsize/BMI-1-Antibody-3E3-Western-Blot-NBP2-22204-img0006.jpg)
![Immunohistochemistry-Paraffin: BMI-1 Antibody (3E3) [NBP2-22204] - Analysis of paraffin-embedded cervical cancer tissues using Bmi1 mouse mAb with DAB staining.](http://images.novusbio.com/fullsize/BMI-1-Antibody-3E3-Immunohistochemistry-Paraffin-NBP2-22204-img0003.jpg)
![ELISA: BMI-1 Antibody (3E3) [NBP2-22204] - Red: Control Antigen (100ng); Purple: Antigen (10ng); Green: Antigen (50ng); Blue: Antigen (100ng)](http://images.novusbio.com/fullsize/BMI-1-Antibody-3E3-ELISA-NBP2-22204-img0005.jpg)
![Western Blot: BMI-1 Antibody [NBP1-87321] - Analysis in U2OS cells transfected with control siRNA, target specific siRNA probe #1,. Remaining relative intensity is presented. Loading control: Anti-PPIB.](http://images.novusbio.com/fullsize/BMI-1-Antibody-Western-Blot-NBP1-87321-img0009.jpg "<b>Genetic Strategies Validation. </b>Western Blot: BMI-1 Antibody [NBP1-87321] - Analysis in U2OS cells transfected with control siRNA, target specific siRNA probe #1,. Remaining relative intensity is presented. Loading control: Anti-PPIB.")
![<b>Genetic Strategies Validation. </b>Immunohistochemistry-Paraffin: BMI-1 Antibody [NBP1-87321] - Staining of human cerebral cortex shows moderate nuclear positivity in glial cells.](http://images.novusbio.com/fullsize/BMI-1-Antibody-Immunohistochemistry-Paraffin-NBP1-87321-img0012.jpg)
![Western Blot: BMI-1 Antibody [NBP1-87321] - Analysis in human cell line HDLM-2.](http://images.novusbio.com/fullsize/BMI-1-Antibody-Western-Blot-NBP1-87321-img0007.jpg)
![Western Blot: BMI-1 Antibody [NBP1-87321] - Analysis in mouse cell line NIH-3T3 and rat cell line NBT-II.](http://images.novusbio.com/fullsize/BMI-1-Antibody-Western-Blot-NBP1-87321-img0008.jpg)
![Immunohistochemistry-Paraffin: BMI-1 Antibody [NBP1-87321] - Staining of human testis shows strong nuclear positivity in cells in seminiferous ducts.](http://images.novusbio.com/fullsize/BMI-1-Antibody-Immunohistochemistry-Paraffin-NBP1-87321-img0010.jpg)
![Immunohistochemistry-Paraffin: BMI-1 Antibody [NBP1-87321] - Staining of human prostate shows moderate nuclear positivity in glandular cells.](http://images.novusbio.com/fullsize/BMI-1-Antibody-Immunohistochemistry-Paraffin-NBP1-87321-img0011.jpg)
![Immunohistochemistry-Paraffin: BMI-1 Antibody [NBP1-87321] - Staining of human placenta shows moderate nuclear positivity in trophoblastic cells.](http://images.novusbio.com/fullsize/BMI-1-Antibody-Immunohistochemistry-Paraffin-NBP1-87321-img0013.jpg)
![Western Blot: BMI-1 Antibody [NBP2-24693] - Analysis of BMI1 in skeletal muscle lysate. Lane 1 shows pre-immune sera. Lanes 2, 3 and 4 show this antibody. I goat anti-rabbit Ig HRP secondary antibody and PicoTect ECL substrate solution were used for this test.](http://images.novusbio.com/fullsize/BMI-1-Antibody-Western-Blot-NBP2-24693-img0006.jpg "Western Blot: BMI-1 Antibody [NBP2-24693] - Analysis of BMI1 in skeletal muscle lysate. Lane 1 shows pre-immune sera. Lanes 2, 3 and 4 show this antibody. I goat anti-rabbit Ig HRP secondary antibody and PicoTect ECL substrate solution were used for this test.")
![Immunocytochemistry/Immunofluorescence: BMI-1 Antibody [NBP2-24693] - Immunofluorescence of BMI1 in human oral squamous cell carcinoma (UPCI:SCC029B) cells. These cells are part of a large collection of HNSCC (head and neck SCC) lines established by the Gollin lab (White et al., 2007). The BMI1 antibody was used at 5 ug/ml. Staining is primarily nuclear, some cytoplasmic staining is also observed. Data courtesy of Hatem Kaseb, MD and Susanne M. Gollin, PhD.](http://images.novusbio.com/fullsize/BMI-1-Antibody-Immunocytochemistry-Immunofluorescence-NBP2-24693-img0004.jpg)
![Immunohistochemistry-Paraffin: BMI-1 Antibody [NBP2-24693] - Analysis of BMI1 in formalin-fixed, paraffin-embedded human cervix tissue using an isotype control (top left) and this antibody (bottom left, right) at 5 ug/ml.](http://images.novusbio.com/fullsize/BMI-1-Antibody-Immunohistochemistry-Paraffin-NBP2-24693-img0005.jpg)
![Western Blot: Bmi1 Antibody [NB110-40823] - Detection of Bmi1 protein in skeletal muscle](http://images.novusbio.com/fullsize/Bmi1-Antibody-Western-Blot-NB110-40823-img0002.jpg "Western Blot: Bmi1 Antibody [NB110-40823] - Detection of Bmi1 protein in skeletal muscle")
![Immunocytochemistry/Immunofluorescence: Bmi1 Antibody [NB110-40823] - BMI1 antibody was tested in HeLa cells with Dylight 488 (green). Nuclei and alpha-tubulin were counterstained with DAPI (blue) and Dylight 550 (red).](http://images.novusbio.com/fullsize/Bmi1-Antibody-Immunocytochemistry-Immunofluorescence-NB110-40823-img0004.jpg)
![Western Blot: p16INK4a/CDKN2A Antibody (OTI4C11) [NBP2-45602] - Analysis of HEK293T cells were transfected with the pCMV6-ENTRY control (Left lane) or pCMV6-ENTRY CDKN2A.](http://images.novusbio.com/fullsize/p16INK4a-CDKN2A-Antibody-OTI4C11-Western-Blot-NBP2-45602-img0008.jpg "Western Blot: p16INK4a/CDKN2A Antibody (OTI4C11) [NBP2-45602] - Analysis of HEK293T cells were transfected with the pCMV6-ENTRY control (Left lane) or pCMV6-ENTRY CDKN2A.")
![Immunocytochemistry/Immunofluorescence: p16INK4a/CDKN2A Antibody (OTI4C11) [NBP2-45602] - Analysis of HepG2 cells.](http://images.novusbio.com/fullsize/p16INK4a-CDKN2A-Antibody-OTI4C11-Immunofluorescence-NBP2-45602-img0003.jpg)
![Immunohistochemistry: p16INK4a/CDKN2A Antibody (OTI4C11) [NBP2-45602] - Analysis of Carcinoma of Human liver tissue.](http://images.novusbio.com/fullsize/p16INK4a-CDKN2A-Antibody-OTI4C11-Immunohistochemistry-NBP2-45602-img0007.jpg)
![Western Blot: p16INK4a/CDKN2A Antibody (OTI4C11) [NBP2-45602] - Analysis of extracts (35ug) from 9 different cell lines (HepG2: Human; HeLa: Human; HT29: Human; A549: Human; COS7: monkey; Jurkat: human; MDCK: Canine; PC12: Rat; MCF7: human)](http://images.novusbio.com/fullsize/p16INK4a-CDKN2A-Antibody-OTI4C11-Western-Blot-NBP2-45602-img0009.jpg)
![Immunocytochemistry/Immunofluorescence: p16INK4a/CDKN2A Antibody (OTI4C11) [NBP2-45602] - Analysis of COS7 cells transiently transfected by pCMV6-ENTRY CDKN2A.](http://images.novusbio.com/fullsize/p16INK4a-CDKN2A-Antibody-OTI4C11-Immunofluorescence-NBP2-45602-img0001.jpg)
![Immunocytochemistry/Immunofluorescence: p16INK4a/CDKN2A Antibody (OTI4C11) [NBP2-45602] - Analysis of HeLa cells.](http://images.novusbio.com/fullsize/p16INK4a-CDKN2A-Antibody-OTI4C11-Immunofluorescence-NBP2-45602-img0002.jpg)
![Immunohistochemistry: p16INK4a/CDKN2A Antibody (OTI4C11) [NBP2-45602] - Analysis of Carcinoma of Human thyroid tissue.](http://images.novusbio.com/fullsize/p16INK4a-CDKN2A-Antibody-OTI4C11-Immunohistochemistry-NBP2-45602-img0004.jpg)
![Immunohistochemistry: p16INK4a/CDKN2A Antibody (OTI4C11) [NBP2-45602] - Analysis of Adenocarcinoma of Human endometrium tissue.](http://images.novusbio.com/fullsize/p16INK4a-CDKN2A-Antibody-OTI4C11-Immunohistochemistry-NBP2-45602-img0005.jpg)
![Immunohistochemistry: p16INK4a/CDKN2A Antibody (OTI4C11) [NBP2-45602] - Analysis of Human liver tissue.](http://images.novusbio.com/fullsize/p16INK4a-CDKN2A-Antibody-OTI4C11-Immunohistochemistry-NBP2-45602-img0006.jpg)
![Western Blot: MCRS1 Antibody [H00010445-B01P] - Western blot analysis of MCRS1 expression in whole testis extracts from 4.5, 6.5, 9.5, 12.5, and 15.5 dpp and adult mice. Each lane was loaded with 50 ug of testis protein extracts. Alpha tubulin was used as internal control. Image collected and cropped by CiteAb from the following publication (//link.springer.com/article/10.1007/s00412-017-0631-z) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/MCRS1-Antibody-Western-Blot-H00010445-B01P-img0007.jpg "Western Blot: MCRS1 Antibody [H00010445-B01P] - Western blot analysis of MCRS1 expression in whole testis extracts from 4.5, 6.5, 9.5, 12.5, and 15.5 dpp and adult mice. Each lane was loaded with 50 ug of testis protein extracts. Alpha tubulin was used as internal control. Image collected and cropped by CiteAb from the following publication (//link.springer.com/article/10.1007/s00412-017-0631-z) licensed under a CC-BY license.")
![Immunocytochemistry/Immunofluorescence: MCRS1 Antibody [H00010445-B01P] - Analysis of purified antibody to MCRS1 on HeLa cell. (antibody concentration 10 ug/ml)](http://images.novusbio.com/fullsize/MCRS1-Antibody-Immunocytochemistry-Immunofluorescence-H00010445-B01P-img0004.jpg)
![Immunohistochemistry-Paraffin: MCRS1 Antibody [H00010445-B01P] - Analysis of purified antibody to MCRS1 on formalin-fixed paraffin-embedded human spleen. (antibody concentration 3 ug/ml)](http://images.novusbio.com/fullsize/MCRS1-Antibody-Immunohistochemistry-Paraffin-H00010445-B01P-img0005.jpg)
![Western Blot: MCRS1 Antibody [H00010445-B01P] - Analysis of MCRS1 expression in transfected 293T cell line by MCRS1 polyclonal antibody. Lane 1: MCRS1 transfected lysate(50.82 KDa). Lane 2: Non-transfected lysate.](http://images.novusbio.com/fullsize/MCRS1-Antibody-Western-Blot-H00010445-B01P-img0006.jpg)
![Western Blot: MCRS1 Antibody [H00010445-B01P] - Identification of interacting partners of PRDM9 by Y2H screening. a Schematic representation of the domain structure of seven PRDM9-interacting proteins identified by Y2H screening. The prey fragments identified in the screens are shown as blue bars underneath each protein. The length (number of amino acid residues) of each full-length protein is indicated on the right. b RNA expression of the PRDM9-interacting proteins in mouse testes (left) & ovaries (right) during meiosis. Data were extracted from RNA-seq data in Margolin et al. (2014) & Soh et al. (2015)). The average gene expression is shown in reads per kilobase per million of reads (RPKM) & fragments per kilobase of transcript per million mapped read (FKPM) for testes & ovaries, respectively. Zoomed-in views of the dashed line boxes are shown below. Spo11 & Spata19 expression were used as positive & negative controls, respectively. c Western blot analysis of PRDM9, CXXC1, PIH1D1, CEP70, & MCRS1 expression in whole testis extracts from 4.5, 6.5, 9.5, 12.5, & 15.5 dpp & adult mice. Each lane was loaded with 50 μg of testis protein extracts. Tubulin alpha was used as internal control Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/28527011), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/h00010445-b01p_mouse-polyclonal-mcrs1-antibody-310202415483646.jpg)
![Immunocytochemistry/Immunofluorescence: SIAH1 Antibody [NB300-974] - Immunofluorescence analysis of paraformaldehyde fixed U2OS cells, permeabilized with 0.15% Triton. Primary incubation 1hr (10ug/ml) followed by Alexa Fluor 488 secondary antibody (2ug/ml), showing mitochondrial/cytoplasmic and nuclear staining. The nuclear stain is DAPI (blue). Negative control: Unimmunized goat IgG (10ug/ml) followed by Alexa Fluor 488 secondary antibody (2ug/ml).](http://images.novusbio.com/fullsize/SIAH1-Antibody-Immunocytochemistry-Immunofluorescence-NB300-974-img0001.jpg "Immunocytochemistry/Immunofluorescence: SIAH1 Antibody [NB300-974] - Immunofluorescence analysis of paraformaldehyde fixed U2OS cells, permeabilized with 0.15% Triton. Primary incubation 1hr (10ug/ml) followed by Alexa Fluor 488 secondary antibody (2ug/ml), showing mitochondrial/cytoplasmic and nuclear staining. The nuclear stain is DAPI (blue). Negative control: Unimmunized goat IgG (10ug/ml) followed by Alexa Fluor 488 secondary antibody (2ug/ml).")
![Western Blot: CIRBP Antibody [NBP3-38286] - Western blot analysis of various lysates using [KO Validated] CIRBP Rabbit pAb at 1:1000 dilution.Secondary antibody: HRP-conjugated Goat anti-Rabbit IgG (H+L) at 1:10000 dilution.Lysates/proteins: 25ug per lane.Blocking buffer: 3% nonfat dry milk in TBST.Detection: ECL Basic Kit.Exposure time: 90s.](http://images.novusbio.com/fullsize/nbp3-38286_rabbit-cirbp-pab-101220241214494.jpg "Western Blot: CIRBP Antibody [NBP3-38286] - Western blot analysis of various lysates using [KO Validated] CIRBP Rabbit pAb at 1:1000 dilution.Secondary antibody: HRP-conjugated Goat anti-Rabbit IgG (H+L) at 1:10000 dilution.Lysates/proteins: 25ug per lane.Blocking buffer: 3% nonfat dry milk in TBST.Detection: ECL Basic Kit.Exposure time: 90s.")
![Immunohistochemistry: CIRBP Antibody [NBP3-38286] - Immunohistochemistry analysis of paraffin-embedded Human breast cancer using [KO Validated] CIRBP Rabbit pAb at dilution of 1:100 (40x lens). Microwave antigen retrieval performed with 0.01M PBS Buffer (pH 7.2) prior to IHC staining.](http://images.novusbio.com/fullsize/nbp3-38286_rabbit-cirbp-pab-101220241214476.jpg)
![Immunohistochemistry: CIRBP Antibody [NBP3-38286] - Immunohistochemistry analysis of paraffin-embedded Mouse testis using [KO Validated] CIRBP Rabbit pAb at dilution of 1:100 (20x lens). Microwave antigen retrieval performed with 0.01M PBS Buffer (pH 7.2) prior to IHC staining.](http://images.novusbio.com/fullsize/nbp3-38286_rabbit-cirbp-pab-101220241233877.jpg)
![Immunohistochemistry: CIRBP Antibody [NBP3-38286] - Immunohistochemistry analysis of paraffin-embedded Rat testis using [KO Validated] CIRBP Rabbit pAb at dilution of 1:100 (40x lens). Microwave antigen retrieval performed with 0.01M PBS Buffer (pH 7.2) prior to IHC staining.](http://images.novusbio.com/fullsize/nbp3-38286_rabbit-cirbp-pab-101220241214454.jpg)
![Immunocytochemistry/ Immunofluorescence: CIRBP Antibody [NBP3-38286] - Immunofluorescence analysis of HeLa cells using [KO Validated] CIRBP Rabbit pAb. Secondary antibody: Cy3-conjugated Goat anti-Rabbit IgG (H+L) at 1:500 dilution. Blue: DAPI for nuclear staining.](http://images.novusbio.com/fullsize/nbp3-38286_rabbit-cirbp-pab-1012202411535866.jpg)
![<b>Genetic Strategies Validation. </b>Western Blot: CIRBP Antibody [NBP3-38286] - Western Blot analysis of lysates from wild type (WT) and CIRBP knockout (KO) 293T cells, using [KO Validated] CIRBP Rabbit pAb at 1:1000 dilution.Secondary antibody: HRP Goat Anti-Rabbit IgG (H+L) at 1:10000 dilution.Lysates/proteins: 25ug per lane.Blocking buffer: 3% nonfat dry milk in TBST.Detection: ECL Basic Kit.Exposure time: 180s.](http://images.novusbio.com/fullsize/nbp3-38286_rabbit-cirbp-pab-31120251704743.jpg)